3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 1
3
Phase 3
2
Phase 1/2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Fallopian Tube Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Ovarian Neoplasms
2
Neoplasms
1
Interventions
Paclitaxel
79
Carboplatin
64
Bevacizumab
33
liposomal doxorubicin
29
Topotecan
28
Gemcitabine
25
Cisplatin
19
olaparib
18
Drug Therapy
12
Doxorubicin
12
Taxes
11
niraparib
9
Docetaxel
6
CP protocol
6
Trabectedin
5
Hyperthermic Intraperitoneal Chemotherapy
5
Etoposide
5
Cyclophosphamide
5
1-dodecylpyridoxal
5
rucaparib
4
pembrolizumab
4
avelumab
4
atezolizumab
4
Immunoglobulin G
4
Ifosfamide
4
Disulfides
4
Dexamethasone
4
Chemotherapy, Adjuvant
4
trebananib
3
fluzoparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Ovarian Neoplasms
×
mirvetuximab soravtansine
×
Clear all
NCT05445778
2026-06-02
GLORIOSA
AbbVie
Phase 3
Active not recruiting
520 enrolled
NCT02631876
2020-10-14
FORWARD I
ImmunoGen, Inc.
Phase 3
Completed
366 enrolled
20 charts